Toll-Like Receptor 9 Expression Levels in Breast Carcinoma Correlate with Improved Overall Survival in Patients Treated with Neoadjuvant Chemotherapy and Could Serve as a Prognostic Marker,Genetic Testing and Molecular Biomarkers

当前位置： X-MOL 学术 › Genet. Test. Mol. Biomark. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Toll-Like Receptor 9 Expression Levels in Breast Carcinoma Correlate with Improved Overall Survival in Patients Treated with Neoadjuvant Chemotherapy and Could Serve as a Prognostic Marker
Genetic Testing and Molecular Biomarkers ( IF 1.1 ) Pub Date : 2021-01-18 , DOI: 10.1089/gtmb.2020.0170
Aradhana Singh ₁ , Arghya Bandyopadhyay ₂ , Narendranath Mukherjee ₃ , Anupam Basu ₁

Affiliation

Aim: Toll-like receptor 9 (TLR9) can recognize the DNA fragments released from chemotherapy-treated cancer cells in tumor tissues and induce an inflammatory response. The aim of the present study was to evaluate the survivability benefit of TLR9 expression levels as a potential prognostic marker in breast cancer patients treated with neoadjuvant chemotherapy (NACT).

中文翻译：

新辅助化学疗法治疗的乳腺癌患者中Toll样受体9表达水平与总生存期改善相关，可以作为预后指标

目的： Toll样受体9（TLR9）可以识别肿瘤组织中经化疗处理的癌细胞释放的DNA片段，并诱导炎症反应。本研究的目的是评估TLR9表达水平作为新辅助化疗（NACT）治疗的乳腺癌患者的潜在预后指标的生存能力。

更新日期：2021-01-20

点击分享查看原文

点击收藏

阅读更多本刊最新论文本刊介绍/投稿指南11